Journal of Vaccine Research 2024, Vol.14, No.3, 147-156 http://medscipublisher.com/index.php/jvr 150 approach demonstrated robust T cell responses and tumor regression in patients with metastatic breast cancer (Li et al., 2022). Furthermore, recent trials have explored the combination of mRNA vaccines with other therapies, such as chemotherapy and immune checkpoint inhibitors. These combination therapies have shown enhanced efficacy, with some patients experiencing complete tumor regression and prolonged survival (Miao et al., 2021). 3.3 Innovative mRNA vaccine platforms Innovative platforms have been developed to optimize the delivery and effectiveness of mRNA vaccines. One such platform involves the use of lipid nanoparticles (LNPs) to encapsulate mRNA, improving its stability and facilitating targeted delivery to DCs. LNP-based mRNA vaccines have demonstrated high transfection efficiency and potent immune responses in preclinical models (Chen et al., 2022). Another cutting-edge approach is the use of self-amplifying mRNA (saRNA) vaccines. These vaccines encode not only the antigen but also the machinery needed for mRNA replication, leading to prolonged antigen expression and stronger immune responses. saRNA vaccines have shown promise in preclinical studies and are currently being evaluated in clinical trials (Duan et al., 2022). Moreover, personalized mRNA vaccine platforms are being developed to tailor treatments to individual patients' tumor profiles. By sequencing a patient's tumor to identify unique mutations and neoantigens, researchers can create bespoke vaccines that target these specific antigens, potentially improving therapeutic outcomes (Li et al., 2022). These innovative platforms and the continuous evolution of mRNA vaccine technology hold great promise for the future of breast cancer treatment, offering the potential for more effective and personalized therapies. 4 Efficacy and Safety of mRNA Vaccines in Breast Cancer Treatment 4.1 Clinical efficacy The clinical efficacy of mRNA vaccines for breast cancer has been demonstrated through various trials and studies, showcasing their potential to significantly improve patient outcomes (Table 1). One of the most notable clinical trials involved an mRNA vaccine targeting the MUC1 antigen in combination with CTLA-4 blockade. This combination therapy resulted in a significant reduction in tumor growth and enhanced overall survival in patients with triple-negative breast cancer (TNBC) (Liu et al., 2018). Another study focusing on personalized mRNA vaccines tailored to patient-specific neoantigens demonstrated robust tumor regression and durable immune responses in patients with metastatic breast cancer (Li et al., 2022). These findings highlight the potential of mRNA vaccines to induce strong anti-tumor activity and improve clinical outcomes. 4.2 Immunogenicity Immunogenicity is a critical factor in evaluating the effectiveness of mRNA vaccines. The ability of these vaccines to induce a potent immune response has been a key focus of recent research. mRNA vaccines have shown to elicit strong cellular and humoral immune responses by presenting antigens to both CD8+ cytotoxic T cells and CD4+ helper T cells. This dual activation leads to a robust and targeted immune response against cancer cells (Vishweshwaraiah and Dokholyan, 2022). Studies have demonstrated that mRNA vaccines can effectively prime the immune system to recognize and attack breast cancer cells, leading to significant tumor reduction and prolonged survival in preclinical models (Miao et al., 2021). Furthermore, mRNA vaccines have been shown to induce memory T cell responses, providing long-term protection against cancer recurrence. 4.3 Safety profiles The safety profiles of mRNA vaccines have been extensively studied, particularly in the context of their use in cancer immunotherapy. mRNA vaccines are generally well-tolerated and have a favorable safety profile compared to traditional cancer treatments. Common side effects are typically mild and include injection site reactions, fever, fatigue, and muscle pain, which are similar to those observed with other types of vaccines (Tan et al., 2023). Serious adverse events are rare, and no evidence suggests that mRNA vaccines cause long-term health issues. Importantly, mRNA vaccines do not integrate into the host genome, eliminating the risk of insertional
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==